{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Safa O"],"funding":["Hormozgan University of Medical Sciences"],"pagination":["841"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7545374"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Objectives</h4>We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.<h4>Trial design</h4>This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.<h4>Participants</h4>Inclusion criteria: 1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran 2. Age ≥18 years (weight ≥35 kg) 3. Hospitalized ≤48 hours 4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR)) 5. Moderate pneumonia and lung involvement in imaging 6. Signing informed consent and willingness of study participant to accept randomization to any as"],"journal":["Trials"],"pubmed_title":["Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial."],"pmcid":["PMC7545374"],"funding_grant_id":["990089"],"pubmed_authors":["Safa O","Hassaniazad M","Hassanipour S","Dadvand H","Davoodian P","Farashahinejad M","Fathalipour M"],"additional_accession":[]},"is_claimable":false,"name":"Effects of Ginger on clinical manifestations and paraclinical features of patients with Severe Acute Respiratory Syndrome due to COVID-19: A structured summary of a study protocol for a randomized controlled trial.","description":"<h4>Objectives</h4>We investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.<h4>Trial design</h4>This is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.<h4>Participants</h4>Inclusion criteria: 1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran 2. Age ≥18 years (weight ≥35 kg) 3. Hospitalized ≤48 hours 4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PCR)) 5. Moderate pneumonia and lung involvement in imaging 6. Signing informed consent and willingness of study participant to accept randomization to any as","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-06-01T01:15:54.133Z","creation":"2025-06-01T01:15:54.133Z"},"accession":"S-EPMC7545374","cross_references":{"pubmed":["33036662"],"doi":["10.1186/s13063-020-04765-6"]}}